MGMT testing for glioma in clinical laboratories: discordance with methylation analyses prevents the implementation of routine immunohistochemistry

Comparative assessment of 5 methods (methylation-specific polymerase chain reaction, methylight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to analyze O6-methylguanine-DNA-methyltranferase in a series of 100 g

(2012) Véronique Quillien et al.   CANCER

MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCR

(2012) Annette Håvik et al.   Journal of Translational Medicine

Prognostic Value of Three Different Methods of MGMT Promoter Methylation Analysis in a Prospective Trial on Newly Diagnosed Glioblastoma

(2012) Arne Christians et al.   PLoS One

O6-Methylguanine-DNA methyltransferase protein expression by immunohistochemistry in brain and non-brain systemic tumours: systematic review and meta-analysis of correlation with methylation-specific polymerase chain reaction

(2011) Marta Brell et al.   BMC CANCER

Tumour and serum MGMT promoter methylation and protein expression in glioblastoma patients

(2011) Carmen Balañá et al.   Clinical & Translational Oncology

Poor reliability and reproducibility of PCR-based testing of O6-methylguanine-DNA methyltransferase gene (MGMT) promoter methylation status in formalin-fixed and paraffin-embedded neurosurgical biopsy specimens

(2011) M. Preusser et al.   CLINICAL NEUROPATHOLOGY

Correlation of MGMT promoter methylation status with gene and protein expression levels in glioblastoma

(2011) Miyuki Uno et al.   Clinics

O6-Methylguanine-DNA Methyltransferase (MGMT) mRNA Expression Predicts Outcome in Malignant Glioma Independent of MGMT Promoter Methylation

(2011) Simone Kreth et al.   PLoS One

The Global DNA Methylation Surrogate LINE-1 Methylation Is Correlated with MGMT Promoter Methylation and Is a Better Prognostic Factor for Glioma

(2011) Fumiharu Ohka et al.   PLoS One

Extent and Patterns of MGMT Promoter Methylation in Glioblastoma- and Respective Glioblastoma-Derived Spheres

(2010) D. Sciuscio et al.   CLINICAL CANCER RESEARCH

Phase I/IIa Study of Cilengitide and Temozolomide With Concomitant Radiotherapy Followed by Cilengitide and Temozolomide Maintenance Therapy in Patients With Newly Diagnosed Glioblastoma

(2010) Roger Stupp et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of Bevacizumab Plus Temozolomide During and After Radiation Therapy for Patients With Newly Diagnosed Glioblastoma Multiforme

(2010) Albert Lai et al.   JOURNAL OF CLINICAL ONCOLOGY

Low-dose fotemustine for recurrent malignant glioma: a multicenter phase II study

(2010) Alessandra Fabi et al.   JOURNAL OF NEURO-ONCOLOGY

Quantitative analysis of O6-methylguanine DNA methyltransferase (MGMT) promoter methylation in patients with low-grade gliomas

(2010) Adrian F. Ochsenbein et al.   JOURNAL OF NEURO-ONCOLOGY

Primer extension based quantitative polymerase chain reaction reveals consistent differences in the methylation status of the MGMT promoter in diffusely infiltrating gliomas (WHO grade II–IV) of adults

(2010) Erik Vassella et al.   JOURNAL OF NEURO-ONCOLOGY

MGMT promoter methylation in malignant gliomas

(2010) Markus J. Riemenschneider et al.   Targeted Oncology

Long-term survivors of glioblastoma: clinical features and molecular analysis

(2009) Yukihiko Sonoda et al.   ACTA NEUROCHIRURGICA

Careful Exclusion of Non-neoplastic Brain Components is Required for an Appropriate Evaluation of O6-methylguanine-DNA Methyltransferase Status in Glioma

(2009) Ken Sasai et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Prognostic impact of O6-methylguanine-DNA methyltransferase silencing in patients with recurrent glioblastoma multiforme who undergo surgery and carmustine wafer implantation

(2009) Philippe Metellus et al.   CANCER

Prognostic Significance of Molecular Markers and Extent of Resection in Primary Glioblastoma Patients

(2009) J. Felsberg et al.   CLINICAL CANCER RESEARCH

Chemoradiotherapy of Newly Diagnosed Glioblastoma With Intensified Temozolomide

(2009) Markus Weiler et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Talampanel With Standard Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma: A Multicenter Phase II Trial

(2009) Stuart A. Grossman et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme

(2009) David M. Peereboom et al.   JOURNAL OF NEURO-ONCOLOGY

MGMT promoter methylation in malignant gliomas: ready for personalized medicine?

(2009) Michael Weller et al.   Nature Reviews Neurology

Identification of regions correlating MGMT promoter methylation and gene expression in glioblastomas

(2009) Sibille Everhard et al.   NEURO-ONCOLOGY

THE CORRELATION AND PROGNOSTIC SIGNIFICANCE OF MGMT PROMOTER METHYLATION AND MGMT PROTEIN IN GLIOBLASTOMAS

(2009) Van Thang Cao et al.   NEUROSURGERY

Molecular Diagnostic Testing in Malignant Gliomas: A Practical Update on Predictive Markers

(2008) Stephen Yip et al.   JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY

Promoter Methylation and Polymorphisms of the MGMT Gene in Glioblastomas: A Population-Based Study

(2008) Izabela Zawlik et al.   NEUROEPIDEMIOLOGY

Prognostic significance of the immunohistochemical expression ofO6-methylguanine-DNA methyltransferase, P-glycoprotein, and multidrug resistance protein-1 in glioblastomas

(2008) Takao Nakagawa et al.   NEUROPATHOLOGY